Abstract 2325P
Background
In KRAS-mutant NSCLC cells, SHOC2:MRAS:PP1C complex boosted RAS GTP loading and MAPK pathway reactivation after initial MEK suppression. Nuclear export protein exportin 1 (XPO1) is dependent on KRAS-mutant NSCLC cells, making XPO1 a druggable vulnerability. MET and SHOC2 are required for spheroid growth in KRAS-mutant NSCLC cell lines. Using structure-based drug design (SBDD), we looked at whether selinexor and tepotinib could bind into the 1) KRAS G12C His-95 groove like sotorasib (KRAS G12C inhibitor); 2) SHOC2 phosphatase complex in comparison with celestrol (SHOC2 inhibitor).
Methods
We carried out an in silico molecular docking approach with KRAS G12C and the SHOC2 complex against selinexor and tepotinib using SBDD to determine the binding affinity, intermolecular interactions, and ligand structure complementarity. Sotorasib-resistant H358 and parental H358 KRAS G12C NSCLC cells were examined. In vitro growth inhibitory assays determined cell viability after 3-day treatment. Western blot analyses were performed.
Results
The molecular docking results are summarized in the table. Selinexor and tepotinib interacted with all the three proteins of the complex, unlike celestrol interacting with SHOC2 and MRAS. Within the His-95 groove of KRAS G12C, selinexor forms an H bond and tepotinib forms a pi-sulphur and an H bond with the mutant cys12 residue. Selinexor in combination with tepotinib and omeprazole (v-ATPase inhibitor) has been analyzed. Signaling pathway analysis to demonstrate the SHOC2 and KRAS G12C inhibition is ongoing.
Conclusions
In silico modeling predicts that selinexor and tepotinib have more interactions and better binding affinity with the target proteins when compared to the standard inhibitors. In vitro data will be presented on the validation of selinexor and tepotinib for repositioning in KRAS G12C NSCLC. Table: 2325P
Target proteins | Ligands | Binding affinity (Kcal/mol) | Number of hydrogen (H) bonds | Other interactions |
SHOC2 complex | Tepotinib | -10.3 | 2 | 3 |
Selinexor | -9.6 | 5 | 6 | |
Celestrol | -8.8 | 3 | 0 | |
KRASG12C | Tepotinib | -9.1 | 2 | 1 |
Selinexor | -9.4 | 6 | 6 | |
Sotorasib | -8.2 | 3 | 2 |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2336P - MiR-155 overexpression regulates epithelial-mesenchymal transition through repressing Quaking in lung cancer cells
Presenter: Jung-Jyh Hung
Session: Poster session 16
2337P - Feasibility of mutation detection in cytological samples from metastasis in patients with metastatic prostate cancer
Presenter: Marina Mencinger
Session: Poster session 16
2338P - The phenotype of tumor-associated macrophages in human high-grade serous ovarian carcinoma
Presenter: Irina Larionova
Session: Poster session 16
2339P - Clinical and genomic correlates of plasma circulating tumor DNA (ctDNA) tumor fraction (TF) in patients with advanced NSCLC
Presenter: Filippo Dall'Olio
Session: Poster session 16
2340P - T-cell immunoglobulin and mucin-domain containing molecule-3 (Tim3) in breast cancer and the impact on penetration of blood brain barrier by cancer cells
Presenter: Xiaoshan Cao
Session: Poster session 16
2341P - Novel therapeutic opportunities in metaplastic breast cancer
Presenter: Fresia Pareja
Session: Poster session 16
2342P - Single tumor cells are a novel prognostic criterion in breast cancer patients
Presenter: Liubov Tashireva
Session: Poster session 16
2343P - Evolution of circulating tumour DNA analysis in France over 5 years
Presenter: Guillaume Herbreteau
Session: Poster session 16
2345P - The possibility of programmed death-ligand 1-related immune modulation in neoadjuvant thermoradiotherapy for rectal cancer
Presenter: seihwan you
Session: Poster session 16
2346P - Spatial and quantified molecular characterization of high endothelial venule predictive of immunotherapy response
Presenter: Kunheng Du
Session: Poster session 16